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Abstract
Endoscopic ultrasound (EUS) is an indispensable method for detection, characterization, and differential diagnosis of solid
pancreatic lesions. Using advanced technologies such as real-time elastography and contrast enhancement, in 90% of cases,
pancreatic ductal adenocarcinoma and other solid lesions (including rare neoplasms and benign lesions) may be dis-
tinguished. EUS-guided ﬁne-needle aspiration is of vital importance for diagnosis of solid pancreatic lesions other than
ductal adenocarcinoma, for staging of suspected or proven pancreatic cancer, and for cytological/histological proof of
unresectable pancreatic cancer. For staging and assessment of resectability of pancreatic cancer, EUS is applied sup-
plementary to computed tomography. This article is part of an expert video encyclopedia.
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Materials
• Longitudinal echoendoscopes: EG-3870 UTK; Pentax Eur-
ope GmbH, Hamburg, Germany.
• Radial echoendoscopes: EG-3670 URK; Pentax Europe
GmbH, Hamburg, Germany.
• Fine needles for endoscopic ultrasound (EUS): 25, 22, and
19 gauges; Cook Medical, Bloomington, IN, USA; Med-
iglobe, Achenmu¨hle, Germany; Olympus Medical, Ham-
burg, Germany; Boston Scientiﬁc, Natick, MA, USA.
• High-end ultrasound platforms; EUB-7500 HV, HI vision
Preirus and Ascendus; Hitachi Medical Systems, Wies-
baden, Germany.
• SonoVues Bracco Imaging, Konstanz, Germany.
Background and Endoscopic Procedure
Detection
EUS is highly sensitive in the detection of solid pancreatic
lesions and is superior compared with computed tomography
(CT) and magnetic resonance cholangiopancreatography.1–4
For detection of solid pancreatic masses, EUS is indicated in
the case of:
• Clinical suspicion of a hormone-producing pancreatic
neuroendocrine tumor (e.g., insulinoma) if radiological
imaging fails to detect the lesion.2
• Inconclusive ﬁndings of transcutaneous ultrasound or
radiological imaging (CT, magnetic resonance tomography
(MRT)) like suspicion of a tumor, focal or diffuse en-
largement, focal structural change, or dilatation of the
pancreatic and/or common bile duct (Table 1).
• Screening for early pancreatic cancer or its precursor lesions
in asymptomatic high-risk individuals; this indication is
currently under discussion.5
In patients with discrete abnormalities of pancreatic im-
aging, abnormal laboratory ﬁndings (elevated CA 19-9 or
lipase), and/or nonspeciﬁc symptoms (abdominal pain and
weight loss), a normal pancreatic EUS examination rules out a
diagnosis of pancreatic cancer.10,11 In a clinical setting like this,
EUS has a high yield (approximately 50%) to establish diag-
nosis of a particular pancreatic disease. In approximately 10%
of cases a pancreatic neoplasm is detected6–9 (Table 1).
Characterization and Differential Diagnosis
A reliable differential diagnosis between ductal pancreatic
adenocarcinoma and the variety of rare solid pancreatic neo-
plasms, mass-forming inﬂammatory lesions, and other benign
solid lesions provides the basis for appropriate treatment de-
cisions. Despite breathtaking developments in radiological
imaging as well as in ultrasound technologies, careful medical
history and clinical examination remain mainstays of differ-
ential diagnosis in solid pancreatic lesions. Some of the rare
This article is part of an expert video encyclopedia. Click here for the full
Table of Contents.
Video Journal and Encyclopedia of GI Endoscopy 593http://dx.doi.org/10.1016/S2212-0971(13)70253-X 
Video available to view or download at doi:10.1016/S2212- 
0971(13)70253-X 
Open access under CC BY-NC-ND license.
solid pancreatic neoplasias are associated with particular
age groups and gender (e.g., acinar cell cancer and solid pseu-
dopapillary tumor), speciﬁc symptoms (neuroendocrine
tumors), or patient’s histories (pancreatic metastases). Gray
scale EUS has limited speciﬁcity in differentiation of solid
pancreatic lesions. However, absence of pancreatic duct dila-
tation has a high negative predictive value for malignant pan-
creatic tumors.12 Contrast-enhanced techniques have been
shown to improve the diagnostic conﬁdence of transabdominal
ultrasound with regard to the distinction of pancreatic
lesions.13–15 Recently, these techniques as well as other ad-
vanced diagnostic tools like real-time elastography and three-
dimensional reconstruction have become available for EUS,
enabling differentiation of typical ductal pancreatic adeno-
carcinoma from other neoplasias and benign solid lesions with
an accuracy of approximately 90%.15–23 EUS-guided ﬁne-nee-
dle aspiration (FNA) has an accuracy of approximately 90% for
diagnosing malignant pancreatic tumors24,25 and is indispens-
able for speciﬁc cytological and/or histological diagnosis of
nonductal pancreatic neoplasms and benign solid lesions.26
Staging and Assessment of Resectability
In all patients with (suspected) pancreatic cancer, the endo-
sonographer should contribute to staging and assessment
of resectability. Staging is performed according to the 7th
edition of the TNM (Tumor node metastasis)-classiﬁcation
(Figure 1).27 In approximately 10–15% of cases, a thorough
EUS examination with EUS-FNA of any suspicious lesion may
reveal ‘occult’ distant metastases not identiﬁed by prior CT
(e.g., mediastinal lymph node metastases, liver metastases,
and peritoneal carcinosis).28,29 These patients have a very poor
prognosis, and surgical exploration should be avoided.30
Pancreatic cancer with inﬁltration of the celiac trunk, hepatic
artery, and/or superior mesenteric artery is regarded as non-
resectable (cT4). Therefore, in all patients with suspected or
proven pancreatic cancer, EUS examination of the visceral
arteries is mandatory. For the detection of arterial invasion,
EUS has at least similar accuracy compared with CT, and
therefore should be performed in addition to CT.4,31
Key Learning Points/Tips and Tricks
• EUS is the most sensitive diagnostic modality for the ex-
clusion as well as for the detection of solid pancreatic lesions.
• Radial and longitudinal scanning echoendoscopes are both
suited to examine the pancreas in the case of suspected
solid pancreatic lesions.
• Longitudinal scanning echoendoscopes are preferred due
to the potential to carry out EUS-FNA.
• Gray scale EUS should be supplemented by advanced EUS
applications (real-time elastography (RTE–EUS), contrast-
enhanced EUS (CE-EUS)) to characterize solid pancreatic
lesions.
• The typical pancreatic ductal adenocarcinoma presents in
EUS:
J as a hypoechoic mass with irregular outline, often ob-
structing the pancreatic ducts (gray scale EUS);
J hard in comparison to the surrounding pancreatic
parenchyma (RTE–EUS);
J hypovascular in comparison with the surrounding
pancreatic parenchyma (low mechanical index CE-EUS
(CELMI-EUS), high mechanical index CE-EUS (CEHMI-
EUS)); and
J with irregular, scarce arterial vascular pattern and no
veins detectable by Pulsed wave (pw) Doppler (CEHMI-
EUS).
• EUS-FNA should be used for cytological and/or histo-
logical diagnosis of solid pancreatic lesions with features
which are not typical for ductal adenocarcinoma (history,
clinical examination, imaging, and EUS).25,32,33
• Using advanced EUS imaging and EUS-FNA, a 90% accuracy
in differentiating ductal adenocarcinoma and other solid
pancreatic lesions (neuroendocrine tumors, metastases and
other rare neoplasms, inﬂammatory pseudotumors, and
intrapancreatic accessory spleen) can be achieved.15,16,18,20–24
• EUS and EUS-FNA should be used for staging of suspected
or proven pancreatic cancer according to the clinical TNM
classiﬁcation.22,23,27,32
• There are several rules for clinical staging according to the
TNM classiﬁcation,34 which have to be applied in the case
of endosonographic staging of pancreatic cancer:
J Never use the term indeterminate for distant metastases
(M) in clinical staging.
J If there is doubt concerning the correct T, N, or M cat-
egory to which a particular case should be assigned,
then the less advanced category should be chosen.
J Use the preﬁx ‘c’ in pretherapeutic clinical staging.
However, a positive ﬁnding of EUS-FNA with cyto-
logical or histological diagnosis of lymph node in-
volvement or distant metastases is classiﬁed pN1 or
pM1, respectively.
J In the case of a negative ﬁnding of EUS-FNA of lymph
node involvement or distant metastasis, do not use the
terms pN0 or pM0; correct classiﬁcations are cN0 or
cM0, respectively.
• In addition to CT, inﬁltration of the celiac trunk and/or the
superior mesenteric artery should be assessed.31
Table 1 Yield of endoscopic ultrasound in patients with inconclusive ﬁndings of CT or MRT: fullness, focal/diffuse enlargement, structural
change, dilated pancreatic duct7common bile duct
Study Patients (n) Neoplasm (%) Chronic pancreatitis (%) Benign ﬁndings (%) Normal ﬁndings (%)
Agarwal et al. 20086 110 9 29 3 59
Singh et al. 20087a 107 21 13 26 33
Horwhat et al. 20098 69 9 13 13 65
Ho et al. 20069 50 8 36 14 42
aThis study included patients with obstructive jaundice.
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Tx Primary tumor cannot be assessed
T0 No evidence of primary tumor
Tis Carcinoma in situ
Staging
Regional lymph nodes are the peripancreatic nodes including proximal mesenteric
and bile duct nodes and:
                - in pancreatic head tumors only: pyloric, celiac nodes
                - body and tail tumors only: splenic hilum and pancreatic tail nodes
T1 Tumor limited to pancreas, ≤ 20 mm
T2 Tumor limited to pancreas, > 20 mm
T3 Tumor extends beyond pancreas, but without involving of celiac
      axis or superior mesenteric artery
N0 No regional lymph node metastases
N1 Regional lymph node metastases
Nx Regional lymph nodes cannot be assessed
T4 Tumor involves celiac axis or superior mesenteric artery
M1 Distant metastases
M0 No distant metastases
Figure 1 Staging of pancreatic cancer according to the 7th edition of the TNM classiﬁcation.27
Treatment according to specific diagnosisRadical surgery
NoResectability?
CT/ MRT +/− EUS/ EUS-FNA
Yes
YesYes
NoSuspected diagnosis:
ductal pancreatic cancer
Hypovascular
only arteries
hand
Iso-/hypervascular
arteries + veins
soft
Gray scale EUS, real-time elastography, and contrast-enhanced EUS
Solid pancreatic lesion
Patients history, age, sex, and clinical symptoms
Stiffness?
Vascularity?
Pw-Dopler: veins?
EUS-FNA
Specific tissue diagnosis
Figure 2 Diagnostic algorithm for EUS-based diagnosis of solid pancreatic lesions.
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• During EUS, on patients with known or suspected pan-
creatic cancer, the endosonographer should thoroughly
look for and sample any visible ascites, suspicious medi-
astinal lymph node, or liver lesion before performing EUS-
FNA of the primary tumor.30,32,33
• EUS-FNA should be used for cytological and/or histo-
logical diagnosis of unresectable pancreatic cancer.25,32,33
• A detailed ﬂow chart was developed as an aid for a struc-
tured diagnostic approach in solid pancreatic lesions
(Figure 2).35
Complications and Risk Factors
Pancreatic EUS is a safe method with a complication rate of
approximately 0.03%.36 Side effects of the application of
ultrasound contrast agents are exceedingly rare. The compli-
cation rate of EUS-guided ﬁne-needle biopsy (FNB) is reported
to be between 1% and 2%.36 A recent systematic review
showed a low morbidity of EUS-guided FNB of solid pan-
creatic lesions of 0.82%.37
Annotations
In cases 1, 7, and 9 cephalad direction (blue or yellow marker)
is on the left side of the screen. In all other cases, longitudinal
scanning was displayed with cephalad direction (yellow
marker) on the right side of the screen.
The following abbreviations are used in the video
presentations:
• 3D: Three-dimensional reconstruction.
• CCDS: Color-coded duplex sonography.
• CD8: Cluster of differentiation 8 (immunohistochemistry
against the CD8-receptor located at cytotoxic T lymphocytes).
• CE-EUS: Contrast-enhanced EUS.
• CELMI-EUS: Contrast-enhanced low mechanical index EUS.
• CEHMI-EUS: Contrast-enhanced high mechanical index
EUS.
• CT: Computed tomography.
• EUS: Endoscopic ultrasound.
• EUS-FNA: EUS-guided ﬁne-needle aspiration.
• EUS-FNB: EUS-guided ﬁne-needle biopsy.
• MRT: Magnetic resonance tomography.
• Pw-Doppler: pulsed wave Doppler.
• TNM: Tumor node metastasis.
Scripted Voiceover
Time
(min:sec)
Voiceover text
0:00–0:12 The ﬁrst part of the video presentation on the role of
endoscopic ultrasound (EUS) in solid pancreatic
lesions deals with the problem of detection.
0:13–0:32 Due to its unrivaled spatial resolution, EUS is the
most accurate technique for the detection and
exclusion of solid pancreatic lesions. EUS is
recommended in the case of inconclusive ﬁndings
of other imaging techniques and for localization of
insulinoma. Screening for early pancreatic cancer
in asymptomatic high-risk individuals is currently
under discussion.
0:33–0:44 A 26-year-old female patient presents with recurrent
unexplained hypoglycemia indicative for
insulinoma. Transabdominal ultrasound, CT and
MRI are inconclusive.
0:45–02:03 EUS reveals a hypoechoic focal pancreatic lesion of
12  7 mm near the portal conﬂuens. (0:57)
Color-coded duplex sonography shows
vascular signals within the tumor, and after
injection of the ultrasound contrast enhancer
SonoVue, arterial hyperenhancement is
demonstrated. (1:20) Real-time elastography
depicts intermediate stiffness, comparable
with the surrounding pancreatic parenchyma.
(1:33) The hypervascularity of the tumor,
which is typical for pancreatic neuroendocrine
tumors, is again shown using contrast-enhanced
endoscopic ultrasound with low mechanical
index. Surgical resection is performed, and
ﬁnal diagnosis is solitary pancreatic
insulinoma.
02:04–02:20 The second case of a 45-year-old woman, who is
examined because of idiopathic acute pancreatitis,
impressively demonstrates the capability of
EUS to also detect very small, sub-centimetric
lesions.
02:21–02:42 Radial EUS excludes a biliary cause of pancreatitis
and demonstrates normal pancreatic parenchyma.
However, a 5 mm small hypoechoic solid lesion of
the pancreatic neck is detected.
02:43–04:44 Longitudinal EUS is performed in order to
characterize the lesion. The pancreatic duct is
slender and may be followed from the hypoechoic
ventral portion of the pancreas to the more
echogenic dorsal pancreas. (03:03) The small
hypoechoic tumor is demonstrated near the portal
conﬂuens. (03:35) Color-coded duplex
sonography shows some vessels in the periphery
of the lesion. (03:48) In real-time elastography the
tumor tissue has a slightly higher stiffness
compared to the surrounding pancreatic
parenchyma. (04:01) The tumor now is sampled
using a 25-Gauge aspiration needle. Three needle
passes are performed. Cytological smears are
prepared. (04:28) Aspirates are highly cellular.
Small monomorphic cells with scant cytoplasm
resembling lymphocytes are arranged in loosely
cohesive groups and pseudorosettes.
Immunocytochemistry is positive for
synaptophysin, and the diagnosis of a non-
functional neuroendocrine pancreatic tumor is
made.
04:45–05:02 The third case proves the ability to diagnose
pancreatic cancer in very early, asymptomatic
stages. An 82-year-old female presents with an
incidental ﬁnding of constantly high values of
serum lipase and marginal dilatation of
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the pancreatic duct in transabdominal
ultrasound.
05:03–06:45 Longitudinal EUS shows a hypoechoic solid mass of
the pancreatic head measuring 13  11 mm,
which is obstructing the main pancreatic duct and
some side branches. (05:36) Real-time
elastography is used to assess the relative
stiffness of tumor tissue compared with the
surrounding pancreatic parenchyma, which
appears predominantly green. The tumor
tissue is displayed in dark-blue color, indicating a
very high stiffness compared to pancreatic
parenchyma. (05:50) Contrast enhanced
endosonography with low mechanical index
reveals hypovascularity of the tumor compared
with the surrounding pancreatic parenchyma.
These ﬁndings are indicative of ductal pancreatic
adenocarcinoma. (06:06) However, the patient
rejects surgical treatment and therefore EUS-
guided biopsy is performed using a 22-Gauge
aspiration needle. (06:31) A small tissue
core is sampled and ﬁxed with formaldehyde.
Histological examination gives proof of
adenocarcinoma.
06:46–08:56 This case of a 50-year-old female patient with
recurrent pancreatitis attacks shows that
detection of pancreatic tumors is much more
difﬁcult in patients with chronic pancreatitis.
Transabdominal ultrasound is compatible with
chronic pancreatitis and a pancreatic head
pseudocyst is demonstrated. Longitudinal EUS
shows typical criteria of chronic pancreatitis, in
particular dilatation and irregular contour of the
main pancreatic duct, dilated side branches, and
non-shadowing hyperechoic parenchymal
reﬂexes. (07:07) Peripancreatic lymph nodes and
a discrete effusion are features of acute
pancreatitis attack. (07:12) In the region of the
pancreatic head a pseudocyst with some debris
inside is found. (07:22) A striking ﬁnding is
hypoechoic tissue at the level of the papilla,
resulting in obstruction of the bile duct (07:50)
and of the pancreatic duct as well. (08:09) As
expected, real-time elastography shows high
tissue stiffness not only of the tumor, but also of
the pancreatic parenchyma. (08:23) SonoVue is
injected, and contrast enhanced endoscopic
ultrasound with low mechanical index is
performed. The suspicious solid tumor of the
ampullary region is apparently hypovascular
compared with pancreatic parenchyma. Diagnosis
is made of an ampullary cancer with obstructive
chronic pancreatitis, and surgical treatment is
decided.
08.57–09:33 The shown clinical cases illustrate the ﬁndings of
several studies showing a high diagnostic yield of
EUS in patients with inconclusive ﬁndings of
radiological imaging, like suspicion of a tumor,
focal or diffuse enlargement of the pancreas,
focal structural changes, or dilatation of the
pancreatic or the common bile duct. Pooled
data of these studies show that in approximately
10% of cases a pancreatic neoplasm is found
by careful examination. Moreover, advanced
endosonographic techniques like real-time
elastography, contrast-enhanced endosonography
and EUS-guided biopsy render possible
speciﬁc diagnoses of these neoplastic
lesions.
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